Edition:
United States

Eisai Co Ltd (4523.T)

4523.T on Tokyo Stock Exchange

7,074JPY
20 Apr 2018
Change (% chg)

¥-19 (-0.27%)
Prev Close
¥7,093
Open
¥7,078
Day's High
¥7,142
Day's Low
¥7,031
Volume
803,700
Avg. Vol
1,212,789
52-wk High
¥7,148
52-wk Low
¥5,402

Chart for

About

Eisai Co., Ltd. is engaged in the research and development, manufacture, sale and import and export of pharmaceuticals. The Company's business segments include pharmaceutical segment and other segment. The pharmaceutical segment is engaged in the research, develop, manufacture and sale of pharmaceuticals for medical use, generic... (more)

Overall

Beta: 0.71
Market Cap(Mil.): ¥2,103,549.00
Shares Outstanding(Mil.): 296.57
Dividend: 80.00
Yield (%): 2.11

Financials

  4523.T Industry Sector
P/E (TTM): 69.95 30.65 33.25
EPS (TTM): 101.41 -- --
ROI: 3.90 13.53 13.13
ROE: 4.91 15.22 14.96

BRIEF-Nichi-Iko Pharmaceutical says business and capital alliance with Eisai

* Says it forms business and capital alliance with Eisai Co Ltd

Mar 28 2018

BRIEF-Anticancer Agent Lenvima Approved For Additional Indication Of Unresectable Hepatocellular Carcinoma In Japan

* ANTICANCER AGENT LENVIMA® (LENVATINIB MESYLATE) APPROVED FOR ADDITIONAL INDICATION OF UNRESECTABLE HEPATOCELLULAR CARCINOMA (HCC) IN JAPAN, FIRST APPROVAL WORLDWIDE FOR LENVIMA FOR HCC

Mar 23 2018

Eisai clinches Merck deal to develop and sell cancer drug, shares soar

(This March 8 story has been corrected to show in the 7th paragraph that Merck will pay, not receive, R&D reimbursement)

Mar 09 2018

CORRECTED-UPDATE 3-Eisai clinches Merck deal to develop and sell cancer drug, shares soar

* Eisai's drug Lenvima already approved in dozens of countries

Mar 09 2018

BRIEF-Eisai Co, Merck Announce Oncology Collaboration For Lenvima

* EISAI CO., LTD. AND MERCK ENTER GLOBAL STRATEGIC ONCOLOGY COLLABORATION FOR LENVIMA® (LENVATINIB MESYLATE)

Mar 07 2018

Merck, Eisai sign deal to further develop, sell Eisai cancer drug

March 7 Merck & Co and Japan's Eisai Co Ltd on Wednesday announced a potential multibillion-dollar collaboration to develop and sell Eisai's cancer drug Lenvima, which is already approved in many countries for two uses.

Mar 07 2018

BRIEF-Morphotek Announces FDA Acceptance Of IND For Cancer Treatment

* MORPHOTEK ANNOUNCES FDA ACCEPTANCE OF INVESTIGATIONAL NEW DRUG APPLICATION FOR NEXT-GENERATION FARLETUZUMAB ANTIBODY-DRUG CONJUGATE MORAB-202

Jan 10 2018

BRIEF-Eisai, Merck Receive Breakthrough Therapy Designation From FDA For Lenvima, Keytruda

* EISAI AND MERCK RECEIVE BREAKTHROUGH THERAPY DESIGNATION FROM FDA FOR LENVIMA® (LENVATINIB MESYLATE) AND KEYTRUDA® (PEMBROLIZUMAB) AS COMBINATION THERAPY FOR ADVANCED AND/OR METASTATIC RENAL CELL CARCINOMA

Jan 09 2018

BRIEF-Eisai Co to invest about $8.8 mln at Vizag plant in India - Nikkei‍​

* Eisai co to invest about $8.8 million to install manufacturing equipment at Vizag plant in India - Nikkei‍​ Source text for Eikon: Further company coverage:

Oct 31 2017

BRIEF-Biogen and Eisai expand existing collaboration agreement to develop and commercialize investigational Alzheimer's disease treatments including phase 3 aducanumab

* Biogen and Eisai expand existing collaboration agreement to develop and commercialize investigational Alzheimer's disease treatments including phase 3 aducanumab

Oct 23 2017

Earnings vs. Estimates